Enhanced cytotoxicity of NK cells against bortezomib-treated patient MM cells
| Patient . | Untreated lysis plus or minus SD, % . | Treated lysis plus or minus SD, % . | Fold increase, no. . | E/T ratio . |
|---|---|---|---|---|
| Allogenic NK | ||||
| 1 | 13.9 ± 2.8 | 39.6 ± 3.9 | 2.8 | 15:1 |
| 2 | 8.6 ± 6.6 | 22.7 ± 5.1 | 2.6 | 14:1 |
| 3 | 6.4 ± 3.0 | 61.5 ± 7.2 | 9.6 | 20:1 |
| 4 | 4.8 ± 2.7 | 19.0 ± 1.7 | 4.0 | 20:1 |
| Autologous NK | ||||
| 5 | 2.6 ± 3.7 | 27.6 ± 4.4 | 10.6 | 15:1 |
| 6 | 0.2 ± 3.4 | 45.9 ± 7.7 | 229.5 | 9:1 |
| Patient . | Untreated lysis plus or minus SD, % . | Treated lysis plus or minus SD, % . | Fold increase, no. . | E/T ratio . |
|---|---|---|---|---|
| Allogenic NK | ||||
| 1 | 13.9 ± 2.8 | 39.6 ± 3.9 | 2.8 | 15:1 |
| 2 | 8.6 ± 6.6 | 22.7 ± 5.1 | 2.6 | 14:1 |
| 3 | 6.4 ± 3.0 | 61.5 ± 7.2 | 9.6 | 20:1 |
| 4 | 4.8 ± 2.7 | 19.0 ± 1.7 | 4.0 | 20:1 |
| Autologous NK | ||||
| 5 | 2.6 ± 3.7 | 27.6 ± 4.4 | 10.6 | 15:1 |
| 6 | 0.2 ± 3.4 | 45.9 ± 7.7 | 229.5 | 9:1 |